Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes

被引:11
作者
Eggert, AO
Andersen, MH
Voigt, H
Schrama, D
Kämpgen, E
Straten, PT
Becker, JC
机构
[1] Univ Wurzburg, Dept Dermatol, D-8700 Wurzburg, Germany
[2] Danish Canc Soc, Dept Tumor Biol, Copenhagen, Denmark
关键词
MAGE; mouse; melanoma; antigen; T cell;
D O I
10.1002/eji.200324618
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunogenic peptide epitopes from tumor-associated antigens serve as targets for cellular immune responses in numerous clinical trials for therapeutic vaccinations. From these it became evident that prevailing questions can only be addressed in animal models. Hence, problems arise from the fact that while for human melanoma many different immunogenic peptide epitopes are known, for mouse melanoma the available selection is very restricted. To overcome this limitation, we applied reverse immunology to identify K-b-restricted epitopes derived of mouse MAGE. Two epitopes which bind strongly to K-b were selected to test for their immunogenicity in vivo. Spleen cells from mice vaccinated by intradermal injection of mature dendritic cells pulsed with these peptides displayed reactivity to the respective epitopes as measured by enzyme-linked immunospot assays and tetramer staining. The processing and presentation of these epitopes was evident by the killing of melanoma cells by the vaccination-induced T cells. Moreover, intravenous challenge with syngeneic melanoma cells demonstrated the protective immunity induced by this vaccination. In summary, we demonstrate the immunogenicity of two K-b-restricted peptide epitopes derived from mouse MAGE proteins which may serve as valuable tool for preclinical evaluation of vaccination strategies.
引用
收藏
页码:3285 / 3290
页数:6
相关论文
共 24 条
[1]  
Andersen MH, 2001, CANCER RES, V61, P869
[2]   Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination:: Cessation of CTL responses is associated with disease progression [J].
Andersen, MH ;
Keikavoussi, P ;
Bröcker, EB ;
Schuler-Thurner, B ;
Jonassen, M ;
Sondergaard, I ;
Straten, PT ;
Becker, JC ;
Kämpgen, E .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) :820-824
[3]   An assay for peptide binding to HLA-Cw*0102 [J].
Andersen, MH ;
Sondergaard, I ;
Zeuthen, J ;
Elliott, T ;
Haurum, JS .
TISSUE ANTIGENS, 1999, 54 (02) :185-190
[4]  
Andersen MH, 1999, J IMMUNOL, V163, P3812
[5]   Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells [J].
Berger, TG ;
Haendle, I ;
Schrama, D ;
Lüftl, M ;
Bauer, N ;
Pedersen, LO ;
Schuler-Thurner, B ;
Hohenberger, W ;
Straten, PT ;
Schuler, G ;
Becker, JC .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) :229-237
[6]   Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma [J].
Bloom, MB ;
PerryLalley, D ;
Robbins, PF ;
Li, Y ;
ElGamil, M ;
Rosenberg, SA ;
Yang, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :453-459
[7]   EXPRESSION OF MAGE GENES IN PRIMARY AND METASTATIC CUTANEOUS MELANOMA [J].
BRASSEUR, F ;
RIMOLDI, D ;
LIENARD, D ;
LETHE, B ;
CARREL, S ;
ARIENTI, F ;
SUTER, L ;
VANWIJCK, R ;
BOURLOND, A ;
HUMBLET, Y ;
VACCA, A ;
CONESE, M ;
LAHAYE, T ;
DEGIOVANNI, G ;
DERAEMAECKER, R ;
BEAUDUIN, M ;
SASTRE, X ;
SALAMON, E ;
DRENO, B ;
JAGER, E ;
KNUTH, A ;
CHEVREAU, C ;
SUCIU, S ;
LACHAPELLE, JM ;
POUILLART, P ;
PARMIANI, G ;
LEJEUNE, F ;
CEROTTINI, JC ;
BOON, T ;
MARCHAND, M .
INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (03) :375-380
[8]  
Eggert AAO, 1999, CANCER RES, V59, P3340
[9]  
Eggert AO, 2002, EUR J IMMUNOL, V32, P122, DOI 10.1002/1521-4141(200201)32:1<122::AID-IMMU122>3.0.CO
[10]  
2-C